Cetera Investment Advisers’s Emergent Biosolutions EBS Stock Holding History

Cetera Investment Advisers’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.87M	Buy	225,483 +6,000	+3%	+$62.1K	﹤0.01%	2335
2025 Q4	$2.71M	Buy	219,483 +3,489	+2%	+$37.4K	﹤0.01%	1951
2025 Q3	$1.91M	Sell	215,994 -142,958	-40%	-$1.11M	﹤0.01%	2208
2025 Q2	$2.29M	Buy	358,952 +2,671	+0.7%	+$15.3K	﹤0.01%	1743
2025 Q1	$1.73M	Buy	356,281 +79,034	+29%	+$654K	﹤0.01%	1847
2024 Q4	$2.65M	Sell	277,247 -107,236	-28%	-$984K	0.01%	1445
2024 Q3	$3.21M	Buy	384,483 +257,852	+204%	+$2.34M	0.01%	1277
2024 Q2	$864K	Sell	126,631 -44,320	-26%	-$191K	﹤0.01%	2184
2024 Q1	$433K	Buy	+170,951	New	+$385K	﹤0.01%	2719

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Cetera Investment Advisers's EBS Position: Q1 2026 in Review

Cetera Investment Advisers increased its Emergent Biosolutions (EBS) stake by 2.7% in Q1 2026, buying an estimated $62.1K and bringing the position to 225,483 shares worth $1.87M. The position accounts for ﹤0.01% of the portfolio, ranked #2335.

Cetera Investment Advisers first reported a position in EBS in Q1 2024 and has held it in 9 quarters since. The position peaked at $3.21M in Q3 2024. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

Cetera Investment Advisers held 225,483 shares of Emergent Biosolutions worth $1.87M as of Q1 2026.
Cetera Investment Advisers bought 6,000 Emergent Biosolutions shares in Q1 2026, an estimated $62.1K.
Emergent Biosolutions made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #2335 holding.
Cetera Investment Advisers first reported a position in Emergent Biosolutions in Q1 2024 and has held it in 9 quarters since.
Cetera Investment Advisers's Emergent Biosolutions position peaked at $3.21M in Q3 2024.
190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.